Patents Assigned to Oncolix, Inc.
  • Compositions and methods for visualizing and eliminating cancer stem cells
    Patent number: 8754035
    Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: June 17, 2014
    Assignee: Oncolix, Inc.
    Inventor: Wen Y. Chen
  • Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
    Patent number: 8754031
    Abstract: The present invention describes compositions and methods for inhibiting cell proliferation comprising a prolactin receptor antagonist and an agent that inactivates the HER2/neu signaling pathway, and methods of use thereof.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: June 17, 2014
    Assignee: Oncolix, Inc.
    Inventors: Wen Yuan Chen, Michele Lynn Scotti
  • Compositions and methods for visualizing and eliminating cancer stem cells
    Patent number: 8648046
    Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: February 11, 2014
    Assignee: Oncolix, Inc.
    Inventor: Wen Y. Chen
  • Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer
    Publication number: 20130231286
    Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.
    Type: Application
    Filed: November 16, 2011
    Publication date: September 5, 2013
    Applicant: ONCOLIX, INC.
    Inventor: Wen Y. Chen
  • Human prolactin antagonist-angiogenesis inhibitor fusion proteins
    Patent number: 8304381
    Abstract: A novel fusion protein, comprising a receptor-antagonizing domain and an angiogenesis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: November 6, 2012
    Assignee: Oncolix, Inc.
    Inventor: Wen Y. Chen
  • COMPOSITIONS AND METHODS FOR VISUALIZING AND ELIMINATING CANCER STEM CELLS
    Publication number: 20100215577
    Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.
    Type: Application
    Filed: February 16, 2010
    Publication date: August 26, 2010
    Applicant: ONCOLIX, INC.
    Inventor: WEN Y. CHEN
  • Multimeric ligands with enhanced stability
    Patent number: 7632809
    Abstract: The present invention provides compositions and methods for making multimeric proteins to increase stability over their monomer. For example, more stable growth hormone and prolactin receptor agonists are provided.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: December 15, 2009
    Assignee: Oncolix, Inc.
    Inventor: Wen Yuan Chen